PureTech Health (PRTC) Competitors

$17.58 +0.07 (+0.38%)

As of 01:56 PM Eastern

PRTC vs. NRIX, VCEL, AGIO, NUVB, and AMLX

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Nurix Therapeutics (NRIX), Vericel (VCEL), Agios Pharmaceuticals (AGIO), Nuvation Bio (NUVB), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.

How does PureTech Health compare to Nurix Therapeutics?

PureTech Health (NASDAQ:PRTC) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

PureTech Health has higher earnings, but lower revenue than Nurix Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.80	-$109.74M	N/A	N/A
Nurix Therapeutics	$71.78M	23.09	-$264.46M	-$3.16	N/A

In the previous week, Nurix Therapeutics had 3 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Nurix Therapeutics and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.94 beat Nurix Therapeutics' score of 0.73 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.0% of PureTech Health shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

Nurix Therapeutics has a consensus price target of $30.46, indicating a potential upside of 90.03%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

PureTech Health has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. PureTech Health's return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Summary

Nurix Therapeutics beats PureTech Health on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Vericel?

Vericel (NASDAQ:VCEL) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Vericel has a net margin of 7.35% compared to PureTech Health's net margin of 0.00%. Vericel's return on equity of 6.41% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
PureTech Health	N/A	N/A	N/A

Vericel presently has a consensus price target of $55.40, indicating a potential upside of 65.35%. Given Vericel's stronger consensus rating and higher possible upside, research analysts clearly believe Vericel is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vericel has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.19	$16.52M	$0.42	79.77
PureTech Health	$4.66M	91.80	-$109.74M	N/A	N/A

In the previous week, Vericel had 19 more articles in the media than PureTech Health. MarketBeat recorded 21 mentions for Vericel and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.94 beat Vericel's score of 0.91 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

0.0% of PureTech Health shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vericel beats PureTech Health on 10 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

0.0% of PureTech Health shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PureTech Health has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. PureTech Health's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
PureTech Health	N/A	N/A	N/A

PureTech Health has lower revenue, but higher earnings than Agios Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	31.53	-$412.78M	-$7.25	N/A
PureTech Health	$4.66M	91.80	-$109.74M	N/A	N/A

Agios Pharmaceuticals presently has a consensus price target of $41.56, indicating a potential upside of 45.07%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Agios Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Agios Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.94 beat Agios Pharmaceuticals' score of 0.91 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PureTech Health beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

PureTech Health has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. PureTech Health's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
PureTech Health	N/A	N/A	N/A

Nuvation Bio currently has a consensus price target of $12.50, indicating a potential upside of 163.44%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nuvation Bio had 4 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Nuvation Bio and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.94 beat Nuvation Bio's score of 0.16 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvation Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

PureTech Health has lower revenue, but higher earnings than Nuvation Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	26.27	-$204.63M	-$0.43	N/A
PureTech Health	$4.66M	91.80	-$109.74M	N/A	N/A

Summary

Nuvation Bio beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Amylyx Pharmaceuticals?

PureTech Health (NASDAQ:PRTC) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

PureTech Health's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Amylyx Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 64.12%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Amylyx Pharmaceuticals had 12 more articles in the media than PureTech Health. MarketBeat recorded 14 mentions for Amylyx Pharmaceuticals and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.94 beat Amylyx Pharmaceuticals' score of -0.10 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market.

PureTech Health has higher earnings, but lower revenue than Amylyx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.80	-$109.74M	N/A	N/A
Amylyx Pharmaceuticals	$87.37M	17.83	-$144.74M	-$1.50	N/A

Summary

Amylyx Pharmaceuticals beats PureTech Health on 8 of the 14 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$427.80M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	N/A	18.77	20.85	25.56
Price / Sales	91.80	263.59	543.57	72.25
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.39	6.77	9.87	6.72
Net Income	-$109.74M	$24.11M	$3.55B	$333.62M
7 Day Performance	3.57%	0.17%	-0.23%	0.35%
1 Month Performance	-2.33%	0.98%	1.47%	4.00%
1 Year Performance	6.81%	78.11%	41.05%	36.32%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	0.515 of 5 stars	$17.58 +0.4%	N/A	+3.0%	$427.80M	$4.66M	N/A	100	News Coverage Gap Up
NRIX Nurix Therapeutics	2.7163 of 5 stars	$15.96 -2.0%	$30.46 +90.9%	+66.3%	$1.68B	$83.98M	N/A	300
VCEL Vericel	3.8498 of 5 stars	$32.94 +0.1%	$55.40 +68.2%	-24.7%	$1.68B	$292.09M	78.43	300	Earnings Report Analyst Downgrade Analyst Revision
AGIO Agios Pharmaceuticals	3.1529 of 5 stars	$28.42 +1.5%	$41.56 +46.2%	+0.1%	$1.66B	$54.03M	N/A	390
NUVB Nuvation Bio	3.0697 of 5 stars	$4.85 +1.8%	$12.50 +158.0%	+118.5%	$1.66B	$62.90M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. NRIX, VCEL, AGIO, NUVB, and AMLX

How does PureTech Health compare to Nurix Therapeutics?

Summary

How does PureTech Health compare to Vericel?

Summary

How does PureTech Health compare to Agios Pharmaceuticals?

Summary

How does PureTech Health compare to Nuvation Bio?

Summary

How does PureTech Health compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. NRIX, VCEL, AGIO, NUVB, and AMLX

How does PureTech Health compare to Nurix Therapeutics?

Which has better earnings and valuation, PRTC or NRIX?

Does the media favor PRTC or NRIX?

Do insiders and institutionals believe in PRTC or NRIX?

Which has more risk and volatility, PRTC or NRIX?

Do analysts recommend PRTC or NRIX?

Is PRTC or NRIX more profitable?

Summary

How does PureTech Health compare to Vericel?

Is VCEL or PRTC more profitable?

Do analysts recommend VCEL or PRTC?

Which has preferable earnings & valuation, VCEL or PRTC?

Does the media refer more to VCEL or PRTC?

Which has more volatility & risk, VCEL or PRTC?

Do institutionals and insiders believe in VCEL or PRTC?

Summary

How does PureTech Health compare to Agios Pharmaceuticals?

Do institutionals and insiders believe in AGIO or PRTC?

Is AGIO or PRTC more profitable?

Which has preferable earnings & valuation, AGIO or PRTC?

Do analysts recommend AGIO or PRTC?

Which has more volatility & risk, AGIO or PRTC?

Does the media refer more to AGIO or PRTC?

Summary

How does PureTech Health compare to Nuvation Bio?

Is NUVB or PRTC more profitable?

Do analysts prefer NUVB or PRTC?

Does the media refer more to NUVB or PRTC?

Do insiders & institutionals believe in NUVB or PRTC?

Which has more risk & volatility, NUVB or PRTC?

Which has better valuation and earnings, NUVB or PRTC?

Summary

How does PureTech Health compare to Amylyx Pharmaceuticals?

Is PRTC or AMLX more profitable?

Do analysts rate PRTC or AMLX?

Does the media prefer PRTC or AMLX?

Do institutionals & insiders believe in PRTC or AMLX?

Which has more risk & volatility, PRTC or AMLX?

Which has stronger valuation and earnings, PRTC or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools